Skip to main content
Retour
BDULF logo

Bangkok Dusit Medical Services Public Company Limited

Qualité des données : 100%
Suracheté
BDULF
OTC Healthcare Medical - Care Facilities
0,66 €
0,00 € (0,00%)
Cap. Boursière : 10,49B
Également cotée sous BDUUY OTC BDUUF OTC
Fourchette du Jour
0,66 € 0,66 €
Fourchette 52 Semaines
0,56 € 0,74 €
Volume
1 000
Moyenne 50J / 200J
0,61 € / 0,63 €
Clôture Précédente
0,66 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 0,7 0,3
P/B 0,1 2,9
ROE % 15,4 3,7
Net Margin % 14,2 3,8
Rev Growth 5Y % 10,6 10,0
D/E 0,2 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 0,00 €
0,00 € – 0,00 €
 120 B 0
FY2026 0,00 €
0,00 € – 0,00 €
 120 B 0

Points Clés

Revenue grew 10,60% annually over 5 years — strong growth
ROE of 15,39% — decent returns on equity
Debt/Equity of 0,17 — conservative balance sheet
Generating 13,02B in free cash flow
P/E of 0,66 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,31%

Croissance

Revenue Growth (5Y)
10,60%
Revenue (1Y)3,29%
Earnings (1Y)-0,95%
FCF Growth (3Y)2,18%

Qualité

Return on Equity
15,39%
ROIC11,22%
Net Margin14,21%
Op. Margin16,56%

Sécurité

Debt / Equity
0,17
Current Ratio0,98
Interest Coverage51,78

Valorisation

P/E Ratio
0,66
P/B Ratio0,10
EV/EBITDA1,17
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,29% Revenue Growth (3Y) 5,11%
Earnings Growth (1Y) -0,95% Earnings Growth (3Y) 4,96%
Revenue Growth (5Y) 10,60% Earnings Growth (5Y) 18,85%
Profitability
Revenue (TTM) 111,42B Net Income (TTM) 15,84B
ROE 15,39% ROA 10,03%
Gross Margin 34,91% Operating Margin 16,56%
Net Margin 14,21% Free Cash Flow (TTM) 13,02B
ROIC 11,22% FCF Growth (3Y) 2,18%
Safety
Debt / Equity 0,17 Current Ratio 0,98
Interest Coverage 51,78 Dividend Yield 0,04%
Valuation
P/E Ratio 0,66 P/B Ratio 0,10
P/S Ratio 0,09 PEG Ratio -19,43
EV/EBITDA 1,17 Dividend Yield 0,04%
Market Cap 10,49B Enterprise Value 21,64B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 111,42B 107,87B 100,85B 91,93B 74,45B
Net Income 15,84B 15,99B 14,38B 12,61B 7,94B
EPS (Diluted) 1,00 1,01 0,90 0,79 0,50
Gross Profit 38,89B 39,80B 37,44B 33,60B 24,99B
Operating Income 18,45B 20,51B 18,94B 16,99B 11,23B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 157,83B 151,51B 143,60B 141,54B 128,45B
Total Liabilities 47,91B 47,59B 44,72B 47,83B 40,69B
Shareholders' Equity 105,81B 100,04B 95,44B 89,88B 83,85B
Total Debt 17,49B 18,36B 18,13B 23,59B 18,83B
Cash & Equivalents 6,34B 7,37B 7,79B 12,67B 10,93B
Current Assets 23,09B 23,66B 23,55B 27,80B 24,40B
Current Liabilities 23,61B 22,01B 18,43B 20,62B 15,86B

Scores de Stratégies

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#113 of 827
63
Custom Contrarian Investing (David Dreman)
#593 of 670
6
Value Defensive Investing (Benjamin Graham)
#278 of 709
34

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Contrarian Investing (David Dreman)
Mar 24, 2026
Entré Defensive Investing (Benjamin Graham)
Mar 24, 2026